Mon Nov 24 06:51:08 UTC 2025: Okay, here’s a summary and a news article based on the provided text:
Summary:
An article published by The Hindu on November 24, 2025 discusses the rising diagnosis and treatment of ADHD in Australia, along with the increasing misuse of stimulant medications like Ritalin and Vyvanse. The increased visibility of ADHD has led to more diagnoses, which is positive but has also created issues with medication misuse. These medications are often misused by individuals seeking cognitive enhancement or recreational highs, leading to potential health problems like tolerance, anxiety, and heart issues. The article points out the need for better regulation, education, and harm reduction strategies to avoid repeating mistakes made with opioid and benzodiazepine misuse in the past. It recommends a balanced approach similar to that used in the United States, incorporating prescription monitoring, clinician training, and community education.
News Article:
ADHD Diagnoses Surge in Australia, Sparking Concerns Over Stimulant Misuse
Melbourne, November 24, 2025 – As awareness of Attention Deficit Hyperactivity Disorder (ADHD) continues to grow in Australia, so too does the use – and misuse – of stimulant medications commonly prescribed to treat the condition, experts warn. Published on The Hindu e-paper, the original article highlights the number of stimulant prescriptions in Australia quadrupled between 2013 and 2023, reaching over 4 million annually. While increased diagnosis and treatment are seen as a positive step, this rise has led to concerns about the non-medical use of drugs like Ritalin and Vyvanse.
Approximately 400,000 Australians, or one in 48 people, have used prescription stimulants non-medically in the past year, with rates even higher among those in their 20s. These drugs are often used as “smart drugs” for cognitive enhancement or recreationally for their stimulant effects.
Experts warn that the misuse of stimulants can lead to a range of health problems, including tolerance, anxiety, insomnia, and cardiovascular issues. They stress the importance of careful medical supervision, including appropriate dosing and regular health monitoring.
The article urges for better regulation, education, and harm reduction strategies. It highlights the potential pitfalls of focusing solely on supply restrictions, drawing parallels to the opioid and benzodiazepine crises. A balanced approach, like those adopted in the United States, that includes prescription drug monitoring, clinician training, and community-based education campaigns is recommended to reduce harms while ensuring access to medication for those who genuinely need it.
Experts say that without proactive measures, Australia risks repeating past mistakes and seeing an increase in black market activity and unregulated online sources for these medications.
First Piper 